Myelofibrosis
📧 Sign up to get email alerts when something new happens for Myelofibrosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-03-12Clinical Trial Update: A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis [Phase 2]
Phase 2 study evaluating tolerability and efficacy of navitoclax alone or in combination with ruxolitinib in myelofibrosis has completed and…
-
CLINICAL_TRIALS research · 2025-03-07Clinical Trial Update: Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating tasquinimod in patients with myelofibrosis who are refractory to or intolerant of JAK2 inhibitors a…
-
CLINICAL_TRIALS trial_result · 2025-03-05Clinical Trial Update: Phase 2 Study of SAR302503 in Patients With Myelofibrosis [Phase 2]
Phase 2 trial of the investigational agent SAR302503 in patients with myelofibrosis has been completed, with results summarized in the updat…
-
CLINICAL_TRIALS trial_result · 2025-03-05Clinical Trial Update: Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis [Phase 3]
This clinical trial update notes the completion of a Phase III study of SAR302503 in intermediate-2 and high-risk myelofibrosis patients.
-
CLINICAL_TRIALS trial_result · 2025-03-05Clinical Trial Update: Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib [Phase 2]
Phase II, open-label, single-arm study evaluating SAR302503 in myelofibrosis patients who were previously treated with ruxolitinib; the tria…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-03-05Clinical Trial Update: A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis [Phase 1, Phase 2]
A long-term Phase 1/2 clinical trial evaluating orally administered SAR302503 in patients with Myelofibrosis has completed, sponsored by Bri…
-
CLINICAL_TRIALS trial_result · 2025-03-05Clinical Trial Update: Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly [Phase 2]
Phase 2 study sponsored by Bristol-Myers Squibb in Japanese patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythem…
-
CLINICAL_TRIALS research · 2025-02-19Clinical Trial Update: 68Ga-FAPI PET/CT Imaging for Diagnosis, Grading, and Efficacy Evaluation of Myelofibrosis.
A recruiting clinical trial evaluating 68Ga-FAPI PET/CT imaging for diagnosing, grading, and evaluating efficacy in primary myelofibrosis.
-
CLINICAL_TRIALS research · 2025-01-29Clinical Trial Update: Unraveling the Role of Extracellular Vesicles-driven Senescence in Myeloproliferative Neoplasms
This clinical trial investigates how extracellular vesicle–driven senescence contributes to myeloproliferative neoplasms, including essentia…
-
CLINICAL_TRIALS research · 2025-01-14Clinical Trial Update: Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies [Phase 1]
This Phase 1 trial from Epigenetix, Inc. is evaluating a dual BET and CBP/p300 inhibitor across targeted advanced solid tumors and hematolog…
-
CLINICAL_TRIALS trial_result · 2025-01-06Clinical Trial Update: Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF) [Phase 1, Phase 2]
A Phase 1/2 trial of Tagraxofusp (SL-401) in chronic myelomonocytic leukemia and myelofibrosis has completed with results posted (January 20…
-
CLINICAL_TRIALS trial_result · 2024-12-30Clinical Trial Update: Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms. [NA]
A completed pilot clinical trial evaluating a diagnostic score to differentiate myeloproliferative neoplasms, including essential thrombocyt…
-
CLINICAL_TRIALS trial_result · 2024-12-18Clinical Trial Update: Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation [Phase 2]
A Phase 2 study evaluating the combination of ruxolitinib and enasidenib in patients with accelerated- or blast-phase myeloproliferative neo…
-
CLINICAL_TRIALS research · 2024-12-05Clinical Trial Update: Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera
A recruiting clinical trial is evaluating ruxolitinib in patients with myelofibrosis, including primary myelofibrosis and myelofibrosis seco…
-
FDA approval · 2024-11-12FDA Approved: VONJO — Supplemental Application (Sobi, Inc.)
FDA approved a supplemental application for VONJO (pacritinib) by Sobi, Inc.
-
CLINICAL_TRIALS research · 2024-11-06Clinical Trial Update: A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis
A post-marketing surveillance study to assess the safety of fedratinib in Korean patients with myelofibrosis, currently recruiting.
-
CLINICAL_TRIALS research · 2024-11-01Clinical Trial Update: Aquagenic Pruritus in Myeloproliferative Neoplasms
A completed clinical trial investigating aquagenic pruritus in patients with myeloproliferative neoplasms.
-
CLINICAL_TRIALS trial_result · 2024-10-30Clinical Trial Update: Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation [Phase 2]
Phase 2 clinical trial update on a Triplex CMV vaccine designed to prevent CMV infection in patients undergoing hematopoietic stem cell tran…
-
CLINICAL_TRIALS trial_result · 2024-10-28Clinical Trial Update: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) [Phase 3]
Phase 3 MANIFEST-2 study of pelabresib (CPI-0610) in myelofibrosis has posted results as of Oct 28, 2024; the trial remains active but not r…
-
CLINICAL_TRIALS trial_result · 2024-10-17Clinical Trial Update: Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects [Phase 1]
This update reports the completion of a Phase 1 study evaluating the drug-drug interaction of pacritinib with cytochrome P450 substrates and…
-
CLINICAL_TRIALS trial_result · 2024-10-09Clinical Trial Update: Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors [Phase 2]
A Phase 2 trial of selinexor in patients with myelofibrosis refractory or intolerant to JAK1/2 inhibitors was terminated, with results poste…
-
CLINICAL_TRIALS trial_result · 2024-10-04Clinical Trial Update: To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) [Phase 3]
A Phase 3 trial (LIMBER-313) evaluating Parsaclisib in combination with Ruxolitinib for myelofibrosis was terminated, with results posted in…
-
FDA approval · 2024-09-23FDA Approved: HYDROXYUREA — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved Teva Pharmaceuticals USA, Inc.'s supplemental application for Hydroxyurea, confirming an updated approval for the generic produ…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213) [Phase 2]
Phase 2 LIMBER-213 evaluated the safety, tolerability, and efficacy of Itacitinib immediate-release tablets in adults with primary or second…
-
CLINICAL_TRIALS research · 2024-08-27Clinical Trial Update: Myeloproliferative Neoplasms (MPNs) Patient Registry
An update on the Myeloproliferative Neoplasms (MPNs) Patient Registry sponsored by University Health Network in Toronto, currently recruitin…